| Hyperlipidemia
Crestor vs Zypitamag
Side-by-side clinical, coverage, and cost comparison for hyperlipidemia.Deep comparison between: Crestor vs Zypitamag with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsZypitamag has a higher rate of injection site reactions vs Crestor based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Zypitamag but not Crestor, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Crestor
Zypitamag
At A Glance
Oral
Once daily
HMG-CoA reductase inhibitor
Oral
Daily
HMG-CoA reductase inhibitor
Indications
- Cardiovascular Diseases
- Hyperlipidemia
- Atherosclerosis
- Hypercholesterolemia, Familial
- Hypertriglyceridemia
- Hyperlipidemia
Dosing
Cardiovascular Diseases, Hyperlipidemia, Atherosclerosis, Hypertriglyceridemia 5-40 mg orally once daily in adults.
Hypercholesterolemia, Familial HeFH: 5-10 mg once daily (ages 8 to <10 years) or 5-20 mg once daily (ages 10+); HoFH: 20 mg once daily (ages 7+); adults: 5-40 mg once daily.
Hyperlipidemia 2 mg to 4 mg orally once daily; recommended starting dose for moderate/severe renal impairment and end-stage renal disease on hemodialysis is 1 mg once daily (use alternative pitavastatin formulation), maximum 2 mg once daily; do not exceed 1 mg once daily with erythromycin; do not exceed 2 mg once daily with rifampin.
Contraindications
- Acute liver failure or decompensated cirrhosis
- Hypersensitivity to rosuvastatin or any excipient in CRESTOR
- Concomitant use of cyclosporine
- Acute liver failure or decompensated cirrhosis
- Hypersensitivity to pitavastatin or any excipients in ZYPITAMAG
Adverse Reactions
Most common (>=2%) headache, nausea, myalgia, asthenia, constipation, arthralgia, dizziness, increased CPK, abdominal pain, diabetes mellitus
Serious myopathy, rhabdomyolysis, immune-mediated necrotizing myopathy, hepatic dysfunction, proteinuria, hematuria, increases in HbA1c and fasting serum glucose
Postmarketing thrombocytopenia, hepatitis, jaundice, hepatic failure, peripheral neuropathy, cognitive impairment, myasthenia gravis, depression, sleep disorders, gynecomastia, interstitial lung disease, DRESS, lichenoid drug eruption
Most common (>=2%) Myalgia, constipation, diarrhea, back pain, pain in extremity
Serious Myopathy, rhabdomyolysis, immune-mediated necrotizing myopathy, hepatic dysfunction, increases in HbA1c and fasting serum glucose
Postmarketing Abdominal discomfort, abdominal pain, dyspepsia, nausea, asthenia, fatigue, malaise, dizziness, hepatitis, jaundice, fatal and non-fatal hepatic failure, angioedema, muscle spasms, myopathy, rhabdomyolysis, hypoesthesia, peripheral neuropathy, cognitive impairment, insomnia, depression, erectile dysfunction, interstitial lung disease, lichen planus
Pharmacology
CRESTOR (rosuvastatin) is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme converting HMG-CoA to mevalonate (a cholesterol precursor); inhibition accelerates hepatic LDL-receptor expression, reducing plasma LDL-C, total cholesterol, and VLDL levels.
Pitavastatin is an HMG-CoA reductase inhibitor that blocks the conversion of HMG-CoA to mevalonate, a rate-limiting step in cholesterol biosynthesis, thereby upregulating LDL receptors, increasing LDL uptake by the liver, and reducing plasma LDL-C and VLDL levels.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Crestor
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (0/12)
Zypitamag
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (9/12)
UnitedHealthcare
Crestor
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Zypitamag
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (1/8)
Humana
Crestor
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Zypitamag
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (2/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Crestor.
No savings programs available for Zypitamag.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CrestorView full Crestor profile
ZypitamagView full Zypitamag profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.